Launched on 6 October 2026Last updated on

BP emergency in pregnancy 🤰

One tool with three tabs: the severe BP emergency, hypertension and pre-eclampsia (classification and delivery), and antihypertensives and magnesium sulphate. An emergency algorithm for severe hypertension in pregnancy, labour and up to 6 weeks postpartum. Two readings 15 min apart confirm acute-onset severe hypertension (≥ 160 and/or ≥ 110 mmHg), which is treated within 30–60 min. The disorder is classified from the BP, platelets, liver enzymes, creatinine and symptoms (ISSHP 2021 and ACOG severe features: chronic or gestational hypertension, pre-eclampsia with or without severe features, HELLP, eclampsia). The first drug is chosen from IV access, asthma, heart block, bradycardia or heart failure (no labetalol) and maternal tachycardia (no hydralazine first), then the ACOG Committee Opinion 767 order set is shown dose by dose with the BP checks between doses. Magnesium sulphate is marked as treatment (eclampsia), indicated (pre-eclampsia with severe features, HELLP, severe gestational hypertension), to consider, not indicated, or contraindicated (myasthenia gravis), with the IV (Zuspan) and IM (Pritchard) regimens, the maintenance pump rate from the bag, dose reduction in kidney impairment, monitoring, toxic levels and calcium gluconate. Below: IV infusions for refractory hypertension (labetalol, nicardipine, hydralazine, nitroglycerin for pulmonary oedema; nitroprusside only as a last resort), oral drugs after control (methyldopa, labetalol, nifedipine) and drugs to avoid, timing of delivery by gestation, and postpartum care with breastfeeding-compatible drugs. ESC 2025 thresholds and targets sit beside ACOG, ISSHP and NICE. The Hypertension and pre-eclampsia tab classifies the disorder from the gestation, BP, labs and clinical and fetal findings and gives oral treatment from 140/90, low-dose aspirin for prevention, the timing and mode of delivery by gestation (37 weeks without severe features, 34 weeks with them, any gestation after stabilisation for eclampsia, HELLP or deterioration), postpartum follow-up and the lifelong cardiovascular risk. The Antihypertensives and MgSO₄ tab lists the oral drugs with doses (methyldopa (Aldomet), labetalol, extended-release nifedipine, then hydralazine, metoprolol, amlodipine and thiazides), the drugs to avoid (ACE inhibitors, ARBs, sacubitril/valsartan, atenolol, MRAs), the emergency order sets, magnesium regimens and breastfeeding choices.

Upload a report, lab sheet or echo picture to fill this calculator automatically.
Timing
Blood pressure
Severe = ≥ 160 and/or ≥ 110 mmHg; confirm on a repeat within 15 min
Laboratory
Leave blank if not done
Symptoms and findings
Drug choice and magnesium safety
Obstetric BP emergency · ACOG / ISSHP / NICE / ESC
Choose the timing and enter the BP (or tick chronic hypertension or a seizure).
Magnesium sulphate regimens and pump rate
Zuspan IV (pump) or Pritchard IM (no pump); continue 24 h after delivery or the last seizure
Loading dose
4 g IV over 15–20 min
100 mL of the bag, or 8 mL of 50% per 4 g diluted
Maintenance
1 g/h = 25 mL/h
ACOG: 4–6 g load, 1–2 g/h; NICE and WHO: 4 g load, 1 g/h.
  • Pritchard IM regimen (no infusion pump)
    WHO 2011 · ACOG
    4 g IV over 5–20 min plus 10 g IM (5 g of 50% deep IM into each buttock, with 1 mL 2% lidocaine), then 5 g IM every 4 h into alternate buttocks for 24 h. Only if reflexes present, RR > 12/min and urine > 100 mL in 4 h.
  • Recurrent seizure: a further 2 g (4 g if > 70 kg) IV over 5 min
    ACOG 2020 · NICE
    Persistent seizures despite magnesium: midazolam or lorazepam, then airway support and brain imaging.
  • Monitor hourly: patellar reflexes, respiratory rate > 12/min, SpO₂, urine > 25–30 mL/h
    ACOG 2020
    Therapeutic level 4.8–8.4 mg/dL (2–3.5 mmol/L). Loss of reflexes > 9.6 mg/dL (> 4 mmol/L), respiratory depression > 12 mg/dL (> 5 mmol/L), cardiac arrest > 30 mg/dL. Levels only with kidney impairment or signs of toxicity.
  • Toxicity: stop the infusion, calcium gluconate 10% 10 mL (1 g) IV over 10 min
    ACOG 2020 · NICE
    Support ventilation; check the serum level.
  • Do not give magnesium in myasthenia gravis
    IIIACOG 2020
    Can precipitate a myasthenic crisis.
  • Caution with nifedipine and other calcium-channel blockers
    ACOG CO 767
    Theoretical neuromuscular blockade and hypotension; usually used together safely with monitoring.
  • Fetal neuroprotection before 32 weeks
    ACOG CO 455
    Birth expected before 32 weeks: magnesium sulphate also reduces cerebral palsy (4 g load, 1 g/h).
Refractory severe hypertension: IV infusions
When BP stays ≥ 160/110 after the order set; with obstetric, anaesthetic and critical care teams
  • Labetalol infusion 1–2 mg/min (start 20 mg/h, double every 30 min to 160 mg/h)
    ACOG CO 767 · NICE
    After the IV bolus steps; continuous maternal ECG and fetal monitoring. Not in asthma, heart block or heart failure.
  • Nicardipine 5 mg/h, increase by 2.5 mg/h every 5–15 min to 15 mg/h
    ACOG CO 767
    Effective and well tolerated in pregnancy; reflex tachycardia, headache. Central line or large vein (phlebitis).
  • Hydralazine infusion 0.5–10 mg/h
    NICE · RCOG
    After 5–10 mg IV boluses; watch for maternal hypotension and fetal distress. Give with a small fluid preload (≤ 500 mL) only if dry.
  • Pulmonary oedema: nitroglycerin 5 µg/min, titrate every 3–5 min to 100 µg/min, with IV furosemide
    ESC 2025
    The preferred drug when severe hypertension comes with pulmonary oedema.
  • Avoid sodium nitroprusside except as a last resort
    ESC 2025 · ACOG
    Fetal cyanide toxicity after 4 h; only for refractory life-threatening hypertension, for the shortest time.

Pump rates in mL/h for labetalol, nicardipine, hydralazine and nitroglycerin: IV drug dosing.

Oral antihypertensives
After acute control, or for non-severe hypertension ≥ 140/90 mmHg
  • Methyldopa (Aldomet)First line
    250 mg 2–3 times daily; up to 3 g/day in 2–4 doses (ACOG 0.5–3 g/day)
    Central α2-agonist with the longest safety record, including child follow-up. Sedation, depression, raised liver enzymes, positive Coombs test. Slow onset (hours to days). Stop within 2 days after birth.
  • LabetalolFirst line
    100 mg twice daily; up to 2400 mg/day in 2–4 doses (ACOG 200–2400 mg/day)
    α1/β-blocker. Avoid in asthma, heart block, bradycardia and decompensated heart failure. Monitor the newborn for bradycardia and hypoglycaemia.
  • Nifedipine extended-releaseFirst line
    30–60 mg once daily, up to 120 mg/day (NICE modified-release 10–20 mg twice daily, up to 40 mg twice daily)
    Dihydropyridine CCB. Headache, flushing, ankle oedema, tachycardia. Do not use the immediate-release capsule for chronic treatment.
  • Hydralazine (oral)Second line
    10–25 mg 3–4 times daily; up to 200–300 mg/day
    Add-on only: reflex tachycardia when used alone; lupus-like syndrome at high doses.
  • MetoprololSecond line
    25–100 mg twice daily
    Acceptable β1-blocker (ESC). Avoid atenolol: fetal growth restriction.
  • AmlodipineSecond line
    5–10 mg once daily
    Less pregnancy data than nifedipine; widely used postpartum.
  • HydrochlorothiazideSecond line
    12.5–50 mg daily
    Can be continued in chronic hypertension already on it (ACOG); avoid in pre-eclampsia (reduced plasma volume).
Avoid in pregnancy
  • Contraindicated: ACE inhibitors, ARBs, sacubitril/valsartan and direct renin inhibitors
    IIIESC 2025
    Fetal renal failure, oligohydramnios, skull and lung hypoplasia in the 2nd and 3rd trimesters; switch before conception or as soon as pregnancy is confirmed.
  • Avoid: atenolol
    IIIESC 2025
    Fetal growth restriction.
  • Avoid: spironolactone and other MRAs
    ESC 2025
    Anti-androgenic effects on the male fetus (eplerenone has limited data).
  • Avoid: sodium nitroprusside except as a last resort
    ESC 2018 · ACOG
    Fetal cyanide toxicity with infusions over 4 h.
  • Do not give immediate-release nifedipine sublingually or chewed
    ACOG CO 767
    Swallow whole; caution with magnesium sulphate (theoretical neuromuscular blockade and hypotension).

Full classification, aspirin prevention and follow-up are in the Hypertension and pre-eclampsia tab; every drug and the postpartum choices in Antihypertensives and MgSO₄.

Print / Save PDF: opens the print dialog with a table of the inputs and result; choose Save as PDF to keep a file. Made on this device only; nothing is uploaded.
References
  1. American College of Obstetricians and Gynecologists. Clinical management guidelines: Emergent therapy for acute-onset, severe hypertension during pregnancy and the postpartum period. ACOG Committee Opinion No. 767. Obstet Gynecol 2019;133:e174-e180.
  2. American College of Obstetricians and Gynecologists. Gestational hypertension and preeclampsia: ACOG Practice Bulletin No. 222. Obstet Gynecol 2020;135:e237-e260.
  3. Magee LA, Brown MA, et al. The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens 2022;27:148-169.
  4. National Institute for Health and Care Excellence. Hypertension in pregnancy: diagnosis and management. NICE guideline NG133, 2019 (updated 2023).
  5. De Backer J, Haugaa KH, et al. 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy. Eur Heart J 2025.
  6. McEvoy JW, McCarthy CP, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J 2024;45:3912-4018.
  7. Tita AT, et al. Treatment for mild chronic hypertension during pregnancy (CHAP). N Engl J Med 2022;386:1781-1792.
  8. Magpie Trial Collaborative Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial. Lancet 2002;359:1877-1890.
  9. World Health Organization. WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia. Geneva: WHO, 2011.
  10. American College of Obstetricians and Gynecologists. Chronic hypertension in pregnancy. ACOG Practice Bulletin No. 203. Obstet Gynecol 2019;133:e26-e50.
  11. American College of Obstetricians and Gynecologists. Medically indicated late-preterm and early-term deliveries. ACOG Committee Opinion No. 831. Obstet Gynecol 2021;138:e35-e39.
  12. The Eclampsia Trial Collaborative Group. Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial. Lancet 1995;345:1455-1463.